CAJ | 학술논문

目的：评价吉西他滨和顺铂（GP）方案化疗同步三维适形放疗（3D -CRT）与序贯化放疗治疗局部晚期非小细胞肺癌（ NSCLC）的近、远期疗效和不良反应。方法2009-01-2012-06将我院收治的不能手术治疗的局部晚期NSCLC患者69例，随机分为2组，试验组（ n＝35）给予同步 GP方案化疗加3D-CRT，对照组（n＝34）给予GP化疗序贯3D-CRT，比较2组患者的近期有效率、远期生存率和不良反应。结果试验组近期有效率为74.3％，对照组为70.6％，差异无统计学意义（ P＞0.05）。试验组1，3年生存率分别为71.4％，23.6％，对照组为64.2％，12.4％，试验组显著高于对照组（ P＜0.05）。试验组放射性食道炎、放射性肺炎发生率显著高于对照组（ P＜0.05）。结论 GP方案化疗同步3D-CRT可显著提高局部晚期NSCLC患者的远期生存率，但治疗相关毒副反应较重。
목적：평개길서타빈화순박（GP）방안화료동보삼유괄형방료（3D -CRT）여서관화방료치료국부만기비소세포폐암（ NSCLC）적근、원기료효화불량반응。방법2009-01-2012-06장아원수치적불능수술치료적국부만기NSCLC환자69례，수궤분위2조，시험조（ n＝35）급여동보 GP방안화료가3D-CRT，대조조（n＝34）급여GP화료서관3D-CRT，비교2조환자적근기유효솔、원기생존솔화불량반응。결과시험조근기유효솔위74.3％，대조조위70.6％，차이무통계학의의（ P＞0.05）。시험조1，3년생존솔분별위71.4％，23.6％，대조조위64.2％，12.4％，시험조현저고우대조조（ P＜0.05）。시험조방사성식도염、방사성폐염발생솔현저고우대조조（ P＜0.05）。결론 GP방안화료동보3D-CRT가현저제고국부만기NSCLC환자적원기생존솔，단치료상관독부반응교중。
Objective To compare the efficacy and adverse reactions between gemcitabine plus cisplatin ( GP) chemotherapy plus three -di-mensional conformal radiation therapy (3D-CRT) and GP chemothera-py followed by radiation therapy for the treatment of locally advanced non-small cell lung cancer (NSCLC).Methods From January, 2009 to June , 2012 , 69 patients with stage Ⅲa or Ⅲb NSCLC randomly re-ceived GP chemotherapy +three-dimensional conformal radiation thera-py (3D-CRT) (trial group, n=35) or GP chemotherapy followed by radiation therapy ( control group , n=34 ).The short -term efficiency , long-term survival rates and side effects were compared between the two groups.Results No significant difference of short -term efficiency was observed between trial group and control group (74.3%versus 70.6%, P>0.05 ).The 1 and 3-year survival rates were 71.4%, 23.6% in trial group and 74.2%, 12.4% in control group , respectively.The 1 and 3 year survival rate in trial group were much higher than that in con-trol group ( P<0.05 ).The incidences of radiation esophagitis and pneu-monia in observation group were much higher than those in control group ( P<0.05 ).Conclusion GP chemotherapy regimen plus 3D -CRT can significantly improve the 1 and 3-year survival rate of patients with advanced NSCLC , but the side effects are much more severe .